CVS Health delivered a powerful earnings beat Wednesday, posting first-quarter results that exceeded Wall Street expectations across all business segments as operational improvements at its Aetna insurance unit drove profitability gains and prompted the healthcare giant to raise its full-year outlook.
The company now expects full-year profit of between $7.30 and $7.50 per share, up from previous guidance of $7 to $7.20 per share. CVS also raised its revenue forecast to at least $405 billion in 2026, up from a prior outlook of at least $400 billion. CFO Brian Newman said the majority of the $5 billion increase was "reflective of the tail winds we're seeing" for insurer Aetna.
Strong Profitability Across Segments
CVS posted net income of $2.94 billion, or $2.30 per share, for the first quarter, compared with net income of $1.78 billion, or $1.41 per share, in the same period a year earlier. Excluding certain items, adjusted earnings were $2.57 per share, above the $2.20 expected by analysts surveyed by LSEG. Revenue was $100.43 billion, compared with the $95.09 billion expected by analysts and up 6.2% from a year earlier.
The company said all of its business segments—insurer Aetna, its retail pharmacy and health services unit—surpassed Wall Street's expectations. The insurance business brought in $35.97 billion in revenue during the quarter, up around 3% from the first quarter of 2025 and above the $33.28 billion expected by analysts.
Operational Efficiency Gains at Aetna
Newman said Aetna's performance reflected underlying strength and organizational changes to processes or technology that have enabled the company to "do things more efficiently." The insurance segment's medical benefit ratio fell to 84.6% from 87.3% a year earlier, compared with analysts' expectation of 86.3%. The year-over-year improvement in the unit was also due to the lack of a premium deficiency reserve, which had been recorded in the same period in 2025.
Newman said medical costs are still too high, but CVS has internal programs to "take cost out of the way we do work" and can better forecast medical cost trends, saying he is happy "we're not getting a lot of surprises." He said CVS now needs to focus on using the same tools to reduce medical costs.
The pharmacy and consumer wellness division posted $31.99 billion in sales, relatively flat from a year earlier and above the $31.70 billion expected by analysts. The unit dispenses prescriptions in CVS' more than 9,000 retail pharmacies and provides services such as vaccinations and diagnostic testing.
Health Services Growth
The health services segment generated $48.24 billion in revenue, up 11% from a year earlier. That unit includes the pharmacy benefits manager Caremark, which negotiates drug discounts with manufacturers on behalf of insurance plans, creates formularies and reimburses pharmacies for prescriptions.
Newman said, "From an investor lens, we said let's put out realistic, reasonable targets and then find pathways to outperform. And we did that throughout at the end of last year and the quarter." He added, "So to beat and raise, which I think is probably the fourth or fifth consecutive, it feels like we're delivering on that." He also said, "So confident in the year, but still taking a cautious or prudent view," noting that medical costs are still too high.
Shares of CVS rose more than 7% on Wednesday.
Why This Matters:
CVS Health's earnings beat demonstrates how private sector operational efficiency and technological improvements can drive profitability even in heavily regulated healthcare markets. The company's ability to reduce its medical benefit ratio through better forecasting and process improvements shows that market-based solutions and internal cost discipline can address healthcare cost challenges without additional government intervention. The improved performance at Aetna, achieved through organizational changes rather than premium increases, illustrates how competitive pressure and management focus can deliver better outcomes for both shareholders and consumers. Newman's acknowledgment that medical costs remain too high, coupled with the company's commitment to further cost reduction, signals that private enterprise continues to seek sustainable solutions to healthcare affordability challenges through innovation and efficiency rather than external mandates.